Preemptive therapy with Venetoclax for high risk stage A Chronic Lymphoid Leukemia patients, a phase II trial of the FILO group. PREVENE (PREemptive VENEtoclax) trial.

Efficacité et prise en charge thérapeutique de la leucémie lymphoïde chronique par Vénétoclax® en situation réelle

A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment

A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment

Étude de Phase 2/3, randomisée, en ouvert, comparant l’Ixazomib/la Dexaméthasone par voie orale et le Pomalidomide/la Dexaméthasone par voie orale dans le myélome multiple en rechute et/ou réfractaire